Ilett Kenneth F, Kristensen Judith H
University of Western Australia, School of Medicine and Pharmacology, Crawley, 6009, Australia.
Expert Opin Drug Saf. 2005 Jul;4(4):745-68. doi: 10.1517/14740338.4.4.745.
Section 1 describes the benefits of breastfeeding to both mother and infant as well as the potential risks to the infant from maternal drug use. The extent of adverse drug-related events and the need for quality information on drug transfer is stated. Section 2 describes the physiology of lactation and the effects of drugs that stimulate or decrease milk production. Section 3 deals with transport mechanisms for drug passage into milk and factors that may modify the infant's exposure to drugs. The critical descriptors of 'absolute' and 'relative' infant dose are defined to give an objective measure of infant exposure to drugs in milk. Section 4 reviews new or commonly used drugs under the headings of analgesics and anti-inflammatory agents, neurological, endocrine, psychotropic and antihypertensive drugs. Section 5 concludes with an expert opinion of the drug industry and drug use in lactation, herbal preparations, the process of 'risk-benefit' analysis, minimising infant exposure, understanding drug-related adverse events and fostering good experimental design for drugs in lactation studies.
第1节介绍了母乳喂养对母亲和婴儿的益处,以及母亲用药对婴儿的潜在风险。阐述了药物相关不良事件的程度以及获取药物转移质量信息的必要性。第2节描述了泌乳的生理学以及刺激或减少乳汁分泌的药物的作用。第3节探讨了药物进入乳汁的转运机制以及可能改变婴儿接触药物情况的因素。定义了“绝对”和“相对”婴儿剂量的关键描述词,以便客观衡量婴儿从乳汁中接触药物的情况。第4节在镇痛药和抗炎药、神经科药物、内分泌药物、精神药物和抗高血压药物等标题下回顾了新的或常用的药物。第5节以药物行业的专家意见以及哺乳期用药、草药制剂、“风险效益”分析过程、尽量减少婴儿接触、了解药物相关不良事件以及促进哺乳期药物研究的良好实验设计作为结尾。